Benzinga · Aug 14, 2026
B of A Securities Maintains Buy on Sana Biotechnology, Lowers Price Target to $6
B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $7 to $6.
SA
NASDAQ · SANA
Sana Biotechnology, Inc.
Healthcare · Biotechnology
$3.91
Up+$0.17 (+4.55%)
Updated Aug 22, 2026, 3:32 AM
SID Score
6.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.33B
- P/E ratio
- -4.72
- Dividend yield
- 0.00%
- 52-week range
- $2.61 – $4.21
- Volume
- 2.93M
- Avg. volume
- 5.83M
Price performance
SANA price history
1M range · 21 trading sessions · Daily adjusted prices
SANA closed at $3.91 after 21 trading sessions, up 22.96% for the selected period.
- Last close
- $3.91
- Period change
- +22.96%
- Period low
- $3.13
- Period high
- $4.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $3.78 | $4.0951 | $3.74 | $3.91 | 2.93M |
| Aug 20, 2026 | $4.06 | $4.08 | $3.73 | $3.74 | 2.75M |
| Aug 19, 2026 | $3.71 | $4.12 | $3.67 | $4.10 | 5.91M |
| Aug 18, 2026 | $3.67 | $3.68 | $3.5602 | $3.63 | 2.1M |
| Aug 17, 2026 | $3.52 | $3.695 | $3.4655 | $3.68 | 1.67M |
| Aug 14, 2026 | $3.64 | $3.64 | $3.365 | $3.55 | 3.71M |
| Aug 13, 2026 | $3.77 | $3.82 | $3.645 | $3.67 | 1.97M |
| Aug 12, 2026 | $3.79 | $3.87 | $3.72 | $3.77 | 1.82M |
| Aug 11, 2026 | $3.65 | $3.81 | $3.54 | $3.79 | 2.52M |
| Aug 10, 2026 | $3.55 | $3.69 | $3.44 | $3.61 | 2.76M |
| Aug 7, 2026 | $3.49 | $3.545 | $3.41 | $3.52 | 2.15M |
| Aug 6, 2026 | $3.505 | $3.6209 | $3.37 | $3.41 | 1.83M |
| Aug 5, 2026 | $3.44 | $3.54 | $3.35 | $3.51 | 3.01M |
| Aug 4, 2026 | $3.24 | $3.415 | $3.24 | $3.40 | 1.71M |
| Aug 3, 2026 | $3.14 | $3.195 | $3.05 | $3.18 | 2.49M |
| Jul 31, 2026 | $3.25 | $3.32 | $3.085 | $3.13 | 2.31M |
| Jul 30, 2026 | $3.17 | $3.30 | $3.17 | $3.25 | 1.65M |
| Jul 29, 2026 | $3.28 | $3.31 | $3.03 | $3.17 | 3.09M |
| Jul 28, 2026 | $3.25 | $3.415 | $3.18 | $3.29 | 3.65M |
| Jul 27, 2026 | $3.23 | $3.465 | $3.23 | $3.28 | 3.58M |
| Jul 24, 2026 | $3.21 | $3.28 | $3.10 | $3.18 | 2.38M |
Latest SANA news
The latest Smart Investors Daily articles mentioning SANA.
Stock researchCompany · Overview
SANA research
Overview
Company profile and research snapshot.
Company profile
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $8.00
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Buy | — |
| Apr 14, 2026 | Wedbush | Outperform | — |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | B of A Securities | Buy | — |
| Nov 7, 2025 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Sana Biotechnology Q2 Adj. EPS $(0.13) Beats $(0.15) Estimate
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16) per share
SeekingAlpha · Jul 25, 2026
Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold
Sana Biotechnology rated Hold: SC451 for type 1 diabetes drives upside, but valuation & dilution risk loom. Click here to read more about the SANA stock.
SeekingAlpha · Jul 22, 2026
Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation
Sana Biotechnology's lead asset still remains to be SC291, repurposed for severe autoimmune disorders instead of blood cancers. See why SANA stock is a buy.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
